Aeglea BioTherapeutics

Aeglea Biotherapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

Company will begin trading on Nasdaq under trading symbol "SYRE" effective November 28, 2023 Biotechnology leader Cameron Turtle, DPhil, appointed as Chief Executive Officer and Member of the Board of Directors alongside industry veterans Jeffrey Albers and Laurie Stelzer Management team with deep IBD experience expanded to advance pipeline of product candidates designed to improve both efficacy and convenience of therapies for IBD patients, including half-life extended antibodies targeting α4β7 (SPY001) and TL1A (SPY002), which are both on track to enter clinical studies in 2024 $205 million of cash, cash equivalents, marketable securities, and restricted cash as of September 30, 2023, with expected runway into 2026 WALTHAM, Mass. , Nov. 27, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) (the "Company" or "Spyre"), a development-stage biotechnology company, today announced its name change to Spyre Therapeutics, Inc. Effective as of market open on November 28, 2023, Spyre will trade on Nasdaq under the ticker symbol "SYRE".

Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD

WALTHAM, Mass. , Nov. 22, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that Aeglea's independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an aggregate of 351,750 shares of common stock and a grant of 18,912 restricted stock units to four non-executive employees as equity inducement awards under the Aeglea BioTherapeutics, Inc. 2018 Equity Inducement Plan, as amended (the "2018 Plan").

Aeglea BioTherapeutics Announces Grants of Inducement Awards

Continued progress across the Company's potentially best-in-class inflammatory bowel disease (IBD) portfolio SPY001, a half-life extended anti-α4β7 antibody, is on track for an expected IND filing in the first half of 2024, with interim healthy volunteer, proof of concept pharmacokinetic data expected year-end 2024 SPY002, a half-life extended anti-TL1A antibody with potential best-in-class picomolar binding affinity for both the monomer and trimer forms of the target, is on track for expected IND filing in the second half of 2024 Stockholder vote scheduled for November 21 to allow conversion of preferred stock to common stock Strengthened leadership team with the appointments of Scott Burrows as Chief Financial Officer and Heidy King-Jones as Chief Legal Officer and Corporate Secretary $205 million  of cash, cash equivalents, marketable securities, and restricted cash as of September 30, 2023, with expected runway into 2026 WALTHAM, Mass. , Nov. 9, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea" or the "Company") (NASDAQ:AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced its third quarter 2023 financial results and provided program and corporate updates.

Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

NEW YORK , Nov. 1, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) on behalf of the company's shareholders.  The investigation seeks to determine whether Aeglea's directors breached their fiduciary duties in connection with recent corporate actions that have caused a decline in Aeglea's stock price.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Aeglea BioTherapeutics (NASDAQ: AGLE)

WALTHAM, Mass. , Oct. 30, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that management will participate in the following investor conferences: Guggenheim 5th Annual Inflammation & Immunology Conference, New York, New York – November 7 th, 2023 Stifel 2023 Annual Healthcare Conference, New York, New York – November 14 th, 2023 Jefferies 2023 London Healthcare Conference, London, UK – November 15-16 th, 2023 To access the webcast of Aeglea's presentations, please visit the "Events & Presentations" page within the Investors section of the Aeglea website at ir.aeglea.com.

Aeglea BioTherapeutics to Participate in Upcoming November Investor Conferences

WALTHAM, Mass. , Sept. 14, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that management will participate in the Stifel 2023 Immunology & Inflammation Virtual Summit.

Aeglea BioTherapeutics to Participate in Upcoming September Conference

WALTHAM, Mass. , Sept. 7, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced it will effect a reverse stock split of all outstanding shares of Aeglea's common stock at a ratio of 1-for-25.

Aeglea BioTherapeutics Announces Reverse Stock Split

Arcutis Biotherapeutics

Scott Burrows, former Arcutis Biotherapeutics CFO, assumes role as Chief Financial Officer  Heidy Abreu King-Jones, former Provention Bio CLO & Corporate Secretary, assumes role as Chief Legal Officer & Corporate Secretary Appointments strengthen Aeglea's leadership team and provides robust financial and corporate stewardship as the company advances a potentially best-in-class inflammatory bowel disease (IBD) portfolio, including parallel lead α4b7 and TL1A programs WALTHAM, Mass. , Sept. 5, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced the appointment of Scott Burrows, as Chief Financial Officer and Heidy Abreu King-Jones as Chief Legal Officer and Corporate Secretary.

Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones

Acquisition of Spyre's assets and concurrent oversubscribed $210.0 million private investment positions the company to advance a potentially best-in-class inflammatory bowel disease (IBD) portfolio, including α4b7 and TL1A programs Sale of legacy pipeline candidate, pegzilarginase, further streamlines operations and increases focus on IBD strategy $236.7 million of cash and cash equivalents and restricted cash as of June 30, 2023 WALTHAM, Mass. , Aug. 11, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea" or the "Company") (NASDAQ:AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced second quarter 2023 financial results and provided program and corporate updates.

Aeglea BioTherapeutics Reports Second Quarter 2023 Financial Results

On July 19, 2023, Polar Capital Holdings Plc (Trades, Portfolio), a London-based investment firm, made a significant move in the biotechnology sector by investing in 3,936,198 shares in Aeglea BioTherapeutics Inc. This transaction marked a 10000.00% change in the firm's portfolio, with the shares purchased at a price of $0.64 each. The total shares held by Polar Capital in Aeglea BioTherapeutics now stand at 3,936,198, making up 0.02% of the firm's portfolio and representing a 5.02% stake in the biotech company.

Polar Capital Holdings Plc Enters Stake in Aeglea BioTherapeutics Inc

Global rights to pegzilarginase in development for Arginase 1 Deficiency sold to Immedica Pharma for $15 million upfront cash proceeds and up to $100 million of contingent milestone payments Marketing Authorisation Application for pegzilarginase is under review by the European Medicines Agency WALTHAM, Mass. , July 27, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ:AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with best-in-class potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that it has entered into an agreement to sell the global rights to pegzilarginase, an investigational treatment for the rare metabolic disease Arginase 1 Deficiency ("ARG1-D"), to Immedica Pharma AB ("Immedica") for $15 million in upfront cash proceeds and up to $100 million in contingent milestone payments.

Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma

Ginkgo Bioworks Holdings

Grab Holdings Ltd

Vroom

Are you looking for the best penny stocks to watch right now? With all of the excitement in the stock market today, you're not alone.

Best Penny Stocks To Watch? 4 Under $5 For Your List

Incannex Healthcare Inc

Polestar Automotive Holding UK PLC

With the uptick of volatility in the stock market today, there's no question as to why penny stocks are red hot. Whether the broader markets are risk-on or risk-off, the stock market is crashing or rallying, or if there's a significant global catalyst, cheap stocks are usually a topic of discussion.

Top Penny Stocks To Buy? 3 To Watch Before Next Week

Canopy Growth

CleanSpark

Sirius XM Holdings Inc

The Fourth of July Holiday in 2023 will see the stock market closed for a full session. But that doesn't mean fewer opportunities to make money in the stock market.

Best Penny Stocks To Buy? 4 To Watch Before July 4th

Amyris

Bionano Genomics

 Clene Nanomedicine

Clearmind Medicine Inc

Cybin

Hyzon Motors

IronNet

NeuroBo Pharmaceuticals Inc

Qurate Retail Inc

Welcome to the world of penny stocks. This is a corner of the stock market that piques interest and raises eyebrows in equal measure.

10 Top Penny Stocks To Watch Right Now For Under $1

Have you ever dreamt of uncovering a hidden gem in the stock market, something that could turn your modest investment into a jackpot? Welcome to the world of penny stocks.

7 Penny Stocks To Watch Right Now For Under $1

AUSTIN, Texas and WALTHAM, Mass. , June 23, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE) today announced that, in connection with the acquisition of Spyre Therapeutics, Inc. ("Spyre"), a majority of the independent members of Aeglea's Board of Directors approved the grant of stock options to new employees (including the new members of management) as equity inducement awards under the Aeglea BioTherapeutics, Inc. 2018 Equity Inducement Plan.

Aeglea BioTherapeutics Announces Grant of Inducement Awards

Aeglea's (AGLE) shares surge as it acquires Spyre Therapeutics, a private company that focuses on developing antibody therapeutics for inflammatory bowel disease.

Aeglea (AGLE) Soars 329% on Acquiring Spyre Therapeutics

Aeglea BioTherapeutics (NASDAQ: AGLE ) stock is undergoing a massive rally on Thursday after it announced its acquisition of Spyre Therapeutics. Aeglea BioTherapeutics has completed its acquisition of the privately-held biotechnology company.

Why Is Aeglea BioTherapeutics (AGLE) Stock Up 392% Today?

The Beachbody Co.

Faraday Future Intelligent Electric

Canoo

Sidus Space

Sonnet BioTherapeutics

Vascular Biogenics

Versus Systems

Stocks that are priced below $5 per share are typically referred to as penny stocks. However, for the purpose of this article, we will be focusing specifically on penny stocks that are priced under $1.

Best Penny Stocks to Buy Under $1? 10 To Watch Now

Acquisition of Spyre and concurrent oversubscribed $210 million private investment positions the company to advance a leading inflammatory bowel disease (IBD) portfolio Spyre, the second spinout from Paragon Therapeutics, is advancing a pipeline of product candidates, led by SPY001 and SPY002, that are potentially best-in-class antibodies targeting a 4 b 7 and TL1A, respectively, and which are expected to enter the clinic in 2024 Combined company expected to have approximately $220 million in cash or cash equivalents at close: expected to fund operations into 2026 Webcast, June 22, 2023 at 9 a.m. ET AUSTIN, Texas and WALTHAM, Mass.

Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics

Aeglea Biotherapeutics (AGLE) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.37 per share a year ago.

Aeglea Biotherapeutics (AGLE) Reports Q1 Loss, Tops Revenue Estimates

$39.8 million of cash and cash equivalents, marketable securities, and restricted cash as of March 31, 2023 AUSTIN, Texas , May 11, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) today announced financial results for the first quarter 2023. First Quarter 2023 Financial Results As of March 31, 2023, Aeglea had available cash and cash equivalents, marketable securities and restricted cash of $39.8 million.

Aeglea BioTherapeutics Reports First Quarter 2023 Financial Results

Aclarion Inc

Astra Space

Credit Suisse

Getaround Inc

Inpixon

Tempo Automation Holdings Inc

VirnetX

Penny stocks under $1 to watch this week. The post 10 Top Penny Stocks To Watch Under $1 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks To Watch Under $1

Penny stocks to watch under $1 this week. The post Penny Stocks to Buy Now?

News for Aeglea BioTherapeutics Stock (AGLE)